First Cases Completed in Australia, New Zealand Using ReValving System for Percutaneous Aortic Valve Replacement

September 9, 2008 - CoreValve said today five clinical evaluation sites (two in New Zealand and three in Australia) have now completed their first series of proctored cases using the company’s proprietary ReValving System for percutaneous aortic valve replacement (PAVR), which features a porcine pericardium valve mounted in a self-expanding frame.

During a 12-day period, 24 patients at hospitals in Auckland, Brisbane, Melbourne, Sydney and Hamilton underwent successful percutaneous aortic valve replacement with CoreValve’s ReValving System. These hospitals are participating in a clinical evaluation registry as required for market clearance in Australia and New Zealand. To date, more than 1,500 patients at 75 sites worldwide have now received a ReValving bioprosthesis since the CE mark was issued.

Physicians will be presenting CoreValve clinical data at the 22nd EACTS (European Association for Cardio-Thoracic Surgery) Annual Meeting in Lisbon, Portugal, which begins Sept. 13.

For more information www.corevalve.com